Previous 10 | Next 10 |
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate dose-dependent improvements in key physiologic and quality of life measures in context of a steroid taper. Efzofitimod treatment reduces pro-inflammatory serum biomarkers in pulmonary sarco...
Global pivotal EFZO-FIT™ study expected to begin in the third quarter of 2022 Primary endpoint will evaluate steroid sparing effect of efzofitimod compared to placebo SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com...
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform, today announced that the company will present at two upcoming i...
aTyr Pharma, Inc. (LIFE) Q1 2022 Earnings Conference Call May 9, 2022, 5:00 PM ET Company Participants Dr. Sanjay S. Shukla – President and Chief Executive Officer Jill Broadfoot – Chief Financial Officer Ashlee Dunston – Director, Investor Relations and Corporate Communi...
aTyr Pharma press release (NASDAQ:LIFE): Q1 GAAP EPS of -$0.44 misses by $0.11. Ended the first quarter 2022 with $98.7 million in cash, cash equivalents and investments. For further details see: aTyr Pharma GAAP EPS of -$0.44 misses by $0.11
Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May. Planned registrational study of efzofitimod in pulmonary sarcoidosis on track to initiate in the third quarter of 2022. ...
LONDON, UK / ACCESSWIRE / May 9, 2022 / Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF) , the brand-led consumer goods company focussed on CBD health and wellness solutions, wishes to provide an update on the temporary suspension of the trading in shares of Love Hemp. As previously announced, t...
LONGDON, ENGLAND / ACCESSWIRE / May 3, 2022 / Love Hemp Group PLC (AQSE:LIFE) (OTCQB:WRHLF) , the brand-led consumer goods company focused on CBD health and wellness solutions, announces that the Aquis Exchange this morning temporarily suspended the trading in shares of Love Hemp. The reason...
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report first quarter 2022 financial results and provide a...
SAN DIEGO, April 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Food and Drug Administration (FDA) has ...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ann...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the c...
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Compa...